S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.23
+1.55
+9.29%
BIO · Bio-Rad Laboratories, Inc.Class A
NEW YORK STOCK EXCHANGE, INC. - BOATS Real Time Price • USD
Bio Rad Laboratories Inc (BIO)
NEW YORK STOCK EXCHANGE, INC.
Life Sciences Tools & Services
$360.15
+5.47
(+1.54%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$360.15
$348.54
$362.10
52-WEEK RANGE
$360.15
$236.73
$396.23
What's happening
- BIO is up 1.54% today, trading at $360.15. — Live quote
- Volume today (25,401) is well below its 3-month average of 281,670. (Finnhub fundamentals)
- Reports earnings on 2026-11-04 (after market close), 13 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $2.62 actual vs. $1.77 estimated (+48.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 1
Buy 4
Hold 4
Sell 1
Strong sell 0
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
BIO
+18.98%
vs S&P 500
+5.61%
1-YEAR RETURN
BIO
+8.82%
vs S&P 500
-6.34%
6-MONTH RETURN
BIO
+20.56%
3-MONTH RETURN
BIO
+17.83%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$2.62
Est. $1.77
BEAT +48.4%
2026-04-26 (Q1 2026)
$1.89
Est. $2.00
MISS -5.7%
2026-01-26 (Q4 2025)
$2.51
Est. $2.73
MISS -8.0%
2025-10-26 (Q3 2025)
$2.26
Est. $1.95
BEAT +15.7%
Valuation Measures & Ratios
Enterprise Value4$10.28B
Forward P/E536.97
PEG Ratio6—
Price / Sales (TTM1)3.71
Price / Book71.10
EV4 / Revenue3.97
EV4 / EBITDA218.34
Profit Margin8.59%
Operating Margin1.82%
Return on Equity (ROE8)3.15%
Return on Assets (ROA9)2.21%
Avg Volume (3M)281,670
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $7.87B | $7.52B | $7.55B | $6.57B | $6.81B |
| P/E | -43.75 | -15.43 | -11.17 | 20.59 | -3.15 |
| Price/Sales | 3.09 | 3.03 | — | — | — |
| Price/Book | 1.10 | 1.10 | 1.12 | 0.92 | 1.02 |
| EV/Revenue | 3.20 | 3.15 | — | — | — |
| ROE | -2.51% | -7.11% | -10.03% | 4.48% | -32.40% |
| ROA | -1.75% | -4.98% | -6.97% | 3.13% | -22.72% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short1,182,765
Change from Prior Settlement+18.44%
% of Float—
Days to Cover (Short Ratio)4.27
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +8.8%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-09-09; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -0.1% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 8.6%. Finnhub fundamentals ↗
- Trailing P/E is 43.2, a high price relative to reported earnings. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BIO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $651.0M | $592.1M | $653.0M | $651.6M | $585.4M | — | $649.7M | $638.5M |
| Gross profit | $345.8M | $309.4M | $343.4M | $345.3M | $306.0M | $342.0M | $355.9M | $355.1M |
| Operating income | $72.6M | $34.1M | $65.3M | $77.1M | $23.7M | — | $64.5M | $101.5M |
| Net income | $371.4M | -$527.1M | -$341.9M | $317.8M | $64.0M | -$715.8M | $653.2M | -$2.17B |
| EPS (diluted) | $13.85 | $-19.55 | $-12.70 | $11.67 | $2.29 | $-25.57 | $23.34 | $-76.26 |
| EPS (basic) | $13.89 | $-19.55 | $-12.70 | $11.67 | $2.29 | $-25.57 | $23.37 | $-76.26 |
| Operating margin | $11 | $6 | $10 | $12 | $4 | — | $10 | $16 |
| Net margin | $57 | -$89 | -$52 | $49 | $11 | — | $101 | -$339 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $10.25B | $9.79B | $10.58B | $9.70B | $10.21B | $9.53B | $9.36B | $10.60B |
| Total liabilities | $3.08B | $2.94B | $3.12B | $2.96B | $3.09B | $2.85B | $2.79B | $3.12B |
| Stockholders' equity | $7.17B | $6.85B | $7.45B | $6.74B | $7.13B | $6.68B | $6.57B | $7.49B |
| Total current assets | $3.02B | $2.94B | $2.91B | $2.84B | $2.81B | $3.04B | $3.03B | $3.06B |
| Total current liabilities | $961.3M | $917.0M | $517.0M | $522.3M | $548.9M | $506.6M | $467.8M | $497.9M |
| Cash & equivalents | $517.0M | $507.2M | $529.8M | $395.8M | $369.3M | $521.4M | $488.1M | $410.4M |
| Marketable securities (current) | $1.10B | $1.06B | $1.01B | $1.02B | $1.00B | $1.14B | $1.18B | $1.21B |
| Accounts receivable | $441.8M | $426.2M | $460.6M | $464.7M | $469.9M | $424.7M | $452.5M | $461.9M |
| Inventory | $780.6M | $770.5M | $740.7M | $783.2M | $798.8M | $790.1M | $760.0M | $804.3M |
| Other current assets | $31.8M | $30.7M | $27.7M | $23.5M | $19.0M | $36.0M | $30.7M | $28.2M |
| Marketable securities (non-current) | $5.72B | $5.31B | $6.10B | $5.06B | $5.58B | $4.99B | $4.84B | $6.00B |
| Property, plant & equipment | — | — | $539.9M | — | — | — | $528.1M | — |
| Goodwill | $574.3M | $577.1M | $579.8M | $578.7M | $581.6M | $414.6M | $410.5M | $415.1M |
| Intangible assets | $160.0M | $166.8M | $174.3M | $388.4M | $396.9M | $296.1M | $293.6M | $307.3M |
| Other non-current assets | — | — | $102.7M | — | — | — | $101.9M | — |
| Accounts payable | $143.5M | $133.1M | $129.0M | $128.8M | $139.3M | $137.9M | $122.3M | $122.2M |
| Deferred revenue (current) | $52.5M | $56.3M | $48.9M | $50.2M | $54.4M | $53.8M | $47.8M | $48.9M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | $158.8M | $153.9M | $141.7M | $127.8M | $175.0M | $131.7M | $147.2M | $142.0M |
| Long-term debt | $803.0M | $802.9M | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B |
| Other non-current liabilities | $198.5M | $198.4M | $199.1M | $207.5M | $209.6M | $173.1M | $177.2M | $197.6M |
| Common stock & paid-in capital | — | — | — | — | — | — | — | — |
| Retained earnings | $8.02B | $7.65B | $8.18B | $7.46B | $7.80B | $7.48B | $7.42B | $8.13B |
| Accumulated other comprehensive income (loss) | -$271.3M | -$235.4M | -$189.1M | -$166.8M | -$154.1M | -$409.8M | -$538.2M | -$315.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $98.7M | $108.1M | $164.9M | $120.9M | $116.5M | $129.9M | $124.2M | $163.6M |
| Investing cash flow | -$66.7M | -$93.2M | -$34.2M | -$43.0M | -$115.4M | $2.9M | -$30.5M | -$55.7M |
| Financing cash flow | -$27.6M | -$44.0M | $3.3M | -$52.5M | -$136.3M | -$97.7M | -$26.2M | -$96.0M |
| Free cash flow | $66.7M | $78.1M | $119.1M | $89.2M | $70.8M | $95.5M | $81.3M | $123.4M |
| Capital expenditures | $32.0M | $30.0M | $45.8M | $31.7M | $45.7M | $34.4M | $42.9M | $40.2M |
| Depreciation & amortization | — | — | $165.4M | — | — | — | $151.6M | — |
| Share-based compensation | $14.5M | $15.0M | $15.9M | $14.9M | $11.9M | $15.3M | $16.4M | $15.6M |
| Deferred income taxes | — | — | $170.5M | — | — | — | -$626.8M | — |
| Change in accounts receivable | $17.6M | -$30.8M | -$3.9M | -$4.2M | $25.7M | -$37.2M | $9.4M | $7.4M |
| Change in inventory | $7.8M | $29.9M | -$51.6M | -$13.6M | -$21.6M | $17.9M | -$24.5M | -$15.2M |
| Purchases of investments | $184.2M | $226.1M | $138.8M | $223.9M | $153.2M | $153.4M | $222.9M | $399.2M |
| Sales/maturities of investments | $126.8M | $145.1M | $147.4M | $200.6M | $274.4M | $171.2M | $205.5M | $364.0M |
| Other investing activities | — | — | — | — | — | — | $0 | — |
| Share repurchases | $31.5M | $47.8M | $0 | $53.4M | $140.2M | $101.9M | $0 | $97.9M |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | $200.0K | $100.0K | $200.0K | $0 | $200.0K | $100.0K | $0 | $100.0K |
| Tax withholding on stock comp | $100.0K | — | $400.0K | $2.5M | $100.0K | — | $100.0K | $3.1M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B |
| Gross profit | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B |
| Operating income | $47.2M | $269.0M | $337.8M | $482.6M | $500.3M |
| Net income | $759.9M | -$1.84B | -$637.3M | -$3.63B | $4.25B |
| EPS (diluted) | $27.85 | $-65.36 | $-21.82 | $-121.79 | $140.83 |
| EPS (basic) | $27.87 | $-65.36 | $-21.82 | $-121.79 | $142.61 |
| Operating margin | $2 | $10 | $13 | $17 | $17 |
| Net margin | $29 | -$72 | -$24 | -$129 | $146 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $10.58B | $9.36B | $12.30B | $13.50B | $17.80B |
| Total liabilities | $3.12B | $2.79B | $3.56B | $3.89B | $4.11B |
| Stockholders' equity | $7.45B | $6.57B | $8.74B | $9.62B | $13.69B |
| Total current assets | $2.91B | $3.03B | $3.05B | $3.16B | $1.99B |
| Total current liabilities | $517.0M | $467.8M | $522.8M | $568.7M | $680.9M |
| Cash & equivalents | $529.8M | $488.1M | $403.8M | $434.2M | $470.8M |
| Marketable securities (current) | $1.01B | $1.18B | $1.20B | $1.36B | $399.1M |
| Accounts receivable | $460.6M | $452.5M | $489.0M | $494.6M | $423.5M |
| Inventory | $740.7M | $760.0M | $780.5M | $719.3M | $572.2M |
| Other current assets | $27.7M | $30.7M | $26.1M | $23.6M | $10.1M |
| Marketable securities (non-current) | $6.10B | $4.84B | $7.70B | $8.83B | $14.39B |
| Property, plant & equipment | $539.9M | $528.1M | $529.0M | $498.6M | $511.6M |
| Goodwill | $579.8M | $410.5M | $413.6M | $406.5M | $347.3M |
| Intangible assets | $174.3M | $293.6M | $320.5M | $332.1M | $253.9M |
| Other non-current assets | $102.7M | $101.9M | $94.9M | $94.6M | $104.2M |
| Accounts payable | $129.0M | $122.3M | $144.6M | $135.0M | $141.9M |
| Deferred revenue (current) | $48.9M | $47.8M | $51.1M | $52.2M | $50.9M |
| Short-term debt | — | — | — | — | — |
| Other current liabilities | $141.7M | $147.2M | $161.6M | $169.6M | $127.9M |
| Long-term debt | $1.20B | $1.20B | $1.20B | $1.20B | — |
| Other non-current liabilities | $199.1M | $177.2M | $195.0M | $195.9M | $182.2M |
| Common stock & paid-in capital | — | — | — | — | — |
| Retained earnings | $8.18B | $7.42B | $9.26B | $9.90B | $13.53B |
| Accumulated other comprehensive income (loss) | -$189.1M | -$538.2M | -$336.0M | -$466.8M | -$175.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $532.2M | $455.2M | $374.9M | $194.4M | $669.5M |
| Investing cash flow | -$189.7M | -$160.2M | $20.2M | -$1.21B | -$797.4M |
| Financing cash flow | -$283.2M | -$218.8M | -$425.6M | $973.6M | -$55.4M |
| Free cash flow | $374.6M | $289.6M | $218.2M | $81.6M | $535.7M |
| Capital expenditures | $157.6M | $165.6M | $156.7M | $112.8M | $133.7M |
| Depreciation & amortization | $165.4M | $151.6M | $145.9M | $137.3M | $137.6M |
| Share-based compensation | $58.0M | $62.3M | $61.3M | $60.9M | $51.2M |
| Deferred income taxes | $170.5M | -$626.8M | -$322.6M | -$1.24B | $1.08B |
| Change in accounts receivable | -$19.6M | -$16.2M | -$11.4M | $87.4M | $20.4M |
| Change in inventory | -$68.9M | -$8.5M | $46.3M | $158.8M | -$46.1M |
| Purchases of investments | $669.3M | $1.28B | $689.0M | $2.06B | $851.6M |
| Sales/maturities of investments | $793.6M | $1.11B | $501.9M | $708.2M | $425.5M |
| Other investing activities | — | $0 | $0 | $1.5M | $0 |
| Share repurchases | $295.5M | $203.6M | $428.7M | $215.7M | $50.0M |
| Debt issued | — | — | — | — | — |
| Debt repaid | $500.0K | $400.0K | $500.0K | $500.0K | $3.0M |
| Tax withholding on stock comp | $3.0M | $3.4M | $14.9M | $14.0M | $22.5M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BIO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-09-06 to 2026-09-06
Recent transactions
- Insiders have net sold 550 shares over the last 182 days, across 0 purchases and 1 sale.
- Most recent: Allison Schwartz (Director) — Option exercise of 92 shares on 2026-09-06.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)550 sh(1 txns)
Net Shares-550
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Allison Schwartz | Director | Option exercise | 2026-09-06 | 92 |
| BARRY JAMES | EVP, President, LSG | Option exercise | 2026-09-06 | 1,056 |
| EVRAN SEDAT | EVP, Global Supply Chain | Option exercise | 2026-09-06 | 864 |
| ENGELHARDT EVA ANETTE | EVP, President, CDG | Option exercise | 2026-09-06 | 1,152 |
| ENLOE COURTNEY C | EVP, General Counsel & Sec | Option exercise | 2026-09-06 | 768 |
| Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Option exercise | 2026-09-06 | 1,536 |
| SCHWARTZ NORMAN D | Chairman & CEO | Option exercise | 2026-09-06 | 3,455 |
| DiVincenzo Jonathan P. | President & COO | Option exercise | 2026-09-05 | 1,712 |
| Mehta Rajat | EVP, GBL Commercial Operations | Option exercise | 2026-09-05 | 456 |
| Hinckley Greg K | Director | Option exercise | 2026-04-21 | 407 |
| PEI MELINDA LITHERLAND | Director | Option exercise | 2026-04-21 | 407 |
| EDWARDS JEFFREY L | Director | Option exercise | 2026-04-21 | 407 |
| PINKSTON ARNOLD A | Director | Option exercise | 2026-04-21 | 407 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-06 | Allison Schwartz | Director | Option exercise | 92 | $0.00 |
| 2026-09-06 | Allison Schwartz | Director | Tax withholding | 34 | $386.11 |
| 2026-09-06 | BARRY JAMES | EVP, President, LSG | Option exercise | 1,056 | $0.00 |
| 2026-09-06 | BARRY JAMES | EVP, President, LSG | Tax withholding | 470 | $386.11 |
| 2026-09-06 | EVRAN SEDAT | EVP, Global Supply Chain | Option exercise | 864 | $0.00 |
| 2026-09-06 | EVRAN SEDAT | EVP, Global Supply Chain | Tax withholding | 277 | $386.11 |
| 2026-09-06 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Option exercise | 1,152 | $0.00 |
| 2026-09-06 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Tax withholding | 485 | $386.11 |
| 2026-09-06 | ENLOE COURTNEY C | EVP, General Counsel & Sec | Option exercise | 768 | $0.00 |
| 2026-09-06 | ENLOE COURTNEY C | EVP, General Counsel & Sec | Tax withholding | 305 | $386.11 |
| 2026-09-06 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Option exercise | 1,536 | $0.00 |
| 2026-09-06 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Tax withholding | 782 | $386.11 |
| 2026-09-06 | SCHWARTZ NORMAN D | Chairman & CEO | Option exercise | 3,455 | $0.00 |
| 2026-09-06 | SCHWARTZ NORMAN D | Chairman & CEO | Tax withholding | 1,854 | $386.11 |
| 2026-09-05 | Allison Schwartz | Director | Option exercise | 228 | $0.00 |
| 2026-09-05 | Allison Schwartz | Director | Tax withholding | 82 | $386.11 |
| 2026-09-05 | BARRY JAMES | EVP, President, LSG | Option exercise | 1,027 | $0.00 |
| 2026-09-05 | BARRY JAMES | EVP, President, LSG | Tax withholding | 369 | $386.11 |
| 2026-09-05 | EVRAN SEDAT | EVP, Global Supply Chain | Option exercise | 1,027 | $0.00 |
| 2026-09-05 | EVRAN SEDAT | EVP, Global Supply Chain | Tax withholding | 329 | $386.11 |
| 2026-09-05 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Option exercise | 1,027 | $0.00 |
| 2026-09-05 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Tax withholding | 369 | $386.11 |
| 2026-09-05 | DiVincenzo Jonathan P. | President & COO | Option exercise | 1,712 | $0.00 |
| 2026-09-05 | DiVincenzo Jonathan P. | President & COO | Tax withholding | 668 | $386.11 |
| 2026-09-05 | ENLOE COURTNEY C | EVP, General Counsel & Sec | Option exercise | 685 | $0.00 |
| 2026-09-05 | ENLOE COURTNEY C | EVP, General Counsel & Sec | Tax withholding | 246 | $386.11 |
| 2026-09-05 | Mehta Rajat | EVP, GBL Commercial Operations | Option exercise | 456 | $0.00 |
| 2026-09-05 | Mehta Rajat | EVP, GBL Commercial Operations | Tax withholding | 233 | $386.11 |
| 2026-09-05 | Mehta Rajat | EVP, GBL Commercial Operations | Option exercise | 1,370 | $0.00 |
| 2026-09-05 | Mehta Rajat | EVP, GBL Commercial Operations | Tax withholding | 504 | $386.11 |
| 2026-09-05 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Option exercise | 1,370 | $0.00 |
| 2026-09-05 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Tax withholding | 559 | $386.11 |
| 2026-09-05 | SCHWARTZ NORMAN D | Chairman & CEO | Option exercise | 4,109 | $0.00 |
| 2026-09-05 | SCHWARTZ NORMAN D | Chairman & CEO | Tax withholding | 2,876 | $386.11 |
| 2026-09-01 | BARRY JAMES | EVP, President, LSG | Option exercise | 425 | $0.00 |
| 2026-09-01 | BARRY JAMES | EVP, President, LSG | Tax withholding | 154 | $380.96 |
| 2026-09-01 | Allison Schwartz | Director | Option exercise | 117 | $0.00 |
| 2026-09-01 | Allison Schwartz | Director | Tax withholding | 43 | $380.96 |
| 2026-09-01 | SCHWARTZ NORMAN D | Chairman & CEO | Option exercise | 5,087 | $0.00 |
| 2026-09-01 | SCHWARTZ NORMAN D | Chairman & CEO | Tax withholding | 2,336 | $380.96 |
| 2026-07-25 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Option exercise | 246 | $0.00 |
| 2026-07-25 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Tax withholding | 89 | $314.46 |
| 2026-05-11 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Open market sale | 550 | $246.54 |
| 2026-04-24 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Option exercise | 1,078 | $0.00 |
| 2026-04-24 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Tax withholding | 420 | $287.84 |
| 2026-04-24 | ENLOE COURTNEY C | EVP, General Counsel & Sec | Option exercise | 186 | $0.00 |
| 2026-04-24 | ENLOE COURTNEY C | EVP, General Counsel & Sec | Tax withholding | 77 | $287.84 |
| 2026-04-21 | Hinckley Greg K | Director | Option exercise | 407 | $0.00 |
| 2026-04-21 | PEI MELINDA LITHERLAND | Director | Option exercise | 407 | $0.00 |
| 2026-04-21 | EDWARDS JEFFREY L | Director | Option exercise | 407 | $0.00 |
| 2026-04-21 | PINKSTON ARNOLD A | Director | Option exercise | 407 | $0.00 |
| 2025-11-06 | BARRY JAMES | EVP, President, LSG | Open market sale | 700 | $306.18 |
| 2025-10-24 | DiVincenzo Jonathan P. | President & COO | Option exercise | 1,869 | $0.00 |
| 2025-10-24 | DiVincenzo Jonathan P. | President & COO | Tax withholding | 950 | $339.75 |
| 2025-10-20 | EVRAN SEDAT | EVP, Global Supply Chain | Option exercise | 1,044 | $0.00 |
| 2025-10-20 | EVRAN SEDAT | EVP, Global Supply Chain | Tax withholding | 335 | $321.90 |
| 2025-09-06 | EVRAN SEDAT | EVP, Global Supply Chain | Option exercise | 864 | $0.00 |
| 2025-09-06 | EVRAN SEDAT | EVP, Global Supply Chain | Tax withholding | 277 | $295.43 |
| 2025-09-06 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Option exercise | 1,535 | $0.00 |
| 2025-09-06 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Tax withholding | 550 | $295.43 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:49 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
Recent news
Headlines about BIO (Bio-Rad Laboratories, Inc.Class A). Links open the publisher — we don’t host full articles.
-
China's Zhong Shanshan to Buy 1 Billion Yuan of Jinbo Bio Shares, Teaming Up With Shanxi's Richest Woman Yang Xia
BigGo Finance · 2026-10-22 -
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts
Yahoo Finance · 2026-10-22 -
MS Bio Jumps 74% on Debut but Slides 15% From Opening Price
Seoul Economic Daily · 2026-10-22 -
Counsel receives 787,300 stock units at Palisade Bio (PALI), subject to service-based vesting.
Stock Titan · 2026-10-21 -
Nuvation Bio Inc. (NUVB) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
INmune Bio Inc. (INMB) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
Tevogen Bio (TVGN) Slips 0.87% to $6.82 as Shares Test Lower End of Recent Range - Reversal Setup Alerts
https://www.siam.in/ · 2026-10-21 -
Doctors may be able to request INmune Bio’s experimental cell therapy before local approval.
Stock Titan · 2026-10-21
No headlines in this category right now — try “All”.